2025-520788-42-00招募中2 期
A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS
Universita Degli Studi Di Milano Bicocca1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2025年1月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
Define the objective response rates (ORR) of PF-06463922 in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Signed and dated Informed Consent approved by Local Ethical Committee before any protocol-specific screening procedures
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- •Female and male patients who are of childbearing potential must agree to use an effective form of contraception (2 forms of contraception) with their partners throughout participation in this study and for at least 90 days after the last dose of treatment
- •ALK+ Lymphoma diagnosed by IHC or FISH
- •Patiets with prior exposure to Brentuximab are eligible for inclusion. The use of Brentuximab is permitted either as first-line or as a subsequent therapy. Refractory/resistant disease is defined as either (i) no achievement of CR or PR during or at the end of at least one prior line of cytotoxic chemotherapy and one prior ALK inhibitor, or (ii) documented progression occurring within 6 months from completion of such treatments
- •Any prior antitumor medical treatment or major surgeries must have been completed at least 14 days prior to initiation of study medication. This could not be respected if there is clear evidence of disease progression, manifested as growing pain attributable to the tumour, fever, growing tumour lesions, increasing LDH values. Systemic anticancer therapy completed within a minimum of 5 half-lives of study entry
- •Able to take oral therapy
- •Female or male, 18 years of age or older
- •ECOG performance status 0-3
- •Adequate organ function as defined by the following criteria: - Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) = 2.5 x upper limit of normal (ULN) or AST and ALT = 5 x ULN if liver function abnormalities are due to underlying malignancy - Total serum bilirubin 1.5 x ULN (except patients with documented Gilbert’s syndrome - Creatinine = 1.5 x ULN
- •Adequate bone marrow function: - Absolute neutrophil count (ANC) = 1000/μL - Platelets = 50.000/μL - Hemoglobin = 9.0 g/dL The hematological values will not be considered in case of bone marrow involvement
排除标准
- •Current treatment on another therapeutic clinical trial
- •Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration
- •Clinically significant cardiovascular disease (that is, active or <3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class = II)
- •Ongoing cardiac dysrhythmias of NCI CTCAE Grade =2: second-degree or third-degree AV block (unless paced) or any AV block with PR >220 msec, uncontrolled atrial fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc >470 msec, or congenital long QT syndrome
- •Pregnancy or breastfeeding
- •Use of drugs or foods that are known strong or moderate CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates
- •Prior malignancy other than basal cell carcinoma , if original diagnosis happened in the last 5 years
- •Patients with predisposing characteristics for acute pancreatitis according to investigator judgment (e.g. uncontrolled hyperglycemia, current gallstone disease, alcoholism)
- •Hypertriglyceridemia ≥ Grade 2, in order to avoid excluding patients with only mild metabolic alterations
- •Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness
结局指标
主要结局
ORR
ORR
次要结局
- Toxicity
- PFS
- OS
- QoL
- Mutational analysis
研究者
Carlo Gambacorti Passerini
Scientific
Universita Degli Studi Di Milano Bicocca
研究点 (1)
Loading locations...
相似试验
已完成
1 期
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)NeuroblastomaNCT03107988New Approaches to Neuroblastoma Therapy Consortium65
招募中
2 期
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseNCT07272499Ruijin Hospital25
已完成
2 期
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)2022-501601-12-00ADC Therapeutics S.A., ADC Therapeutics S.A.28
招募中
2 期
A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not Responsive After Treatment or Who Had Myeloma Which Has Returned After a Period of Treatment2023-508727-12-00Celgene Corp.46
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Resected Stage Ib (tumors ≥ 4 cm) to Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer2023-506861-76-00F. Hoffmann-La Roche AG55